# EDGAR Filing Document

**Accession Number:** 0001707797
**File Stem:** 0001493152-23-005658
**Filing Date:** 2023-2
**Character Count:** 6905
**Document Hash:** 009b787859a6ca5ab6ff07d3a6fc6644
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-005658.hdr.sgml**: 20230221

**ACCESSION NUMBER**: 0001493152-23-005658

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230216

**FILED AS OF DATE**: 20230221

**DATE AS OF CHANGE**: 20230221

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Jain Rita
- **CENTRAL INDEX KEY:** 0001707797

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-15006
- **FILM NUMBER:** 23648466

**MAIL ADDRESS:**
- **STREET 1:** C/O AKEBIA THERAPEUTICS, INC.
- **STREET 2:** 245 FIRST STREET, SUITE 1100
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Celldex Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0000744218
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **IRS NUMBER:** 133191702
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 53 FRONTAGE ROAD
- **STREET 2:** SUITE 220
- **CITY:** HAMPTON
- **STATE:** NJ
- **ZIP:** 08827
- **BUSINESS PHONE:** 908-200-7500

**MAIL ADDRESS:**
- **STREET 1:** 53 FRONTAGE ROAD
- **STREET 2:** SUITE 220
- **CITY:** HAMPTON
- **STATE:** NJ
- **ZIP:** 08827

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AVANT IMMUNOTHERAPEUTICS INC
- **DATE OF NAME CHANGE:** 19980828

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** T CELL SCIENCES INC
- **DATE OF NAME CHANGE:** 19920703

## Ex-24

**Exhibit 24**

**POWER OF ATTORNEY**

Know all by those present, that the undersigned hereby constitutes and appoints each of Sam Martin and Anthony S. Marucci her true and lawful attorney-in-fact to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. execute
 for and on behalf of the undersigned Schedules 13D and 13G, Form ID, and Forms 3, 4 and 5 in accordance with Sections 13 and 16(a)
 of the Securities Exchange Act of 1934 and the rules thereunder;

2. do
 and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any
 such Schedules 13D or 13G, Form ID and Forms 3, 4 or 5, and the timely filing of such Forms with the United States Securities and
 Exchange Commission and any other authority; and

3. take
 any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of
 benefit to, in the best interest of, or legally required by, the undersigned, including without limitation the execution and filing
 of a Form 4 with respect to a transaction which may be reported on a Form 5, it being understood that the documents executed by such
 attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms
 and conditions as such attorney-in-fact may approve in his discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary and proper to be done in the exercise of any of the rights and powers herein granted, as fully and to all intents and purposes as he might or could do in person, with full power of substitution and resubstitution, hereby ratifying and confirming all that such attorney-in-fact, or his substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming any of the undersigned's responsibilities to comply with Sections 13 and 16 of the Securities Exchange Act of 1934.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 10th day of February, 2023.

---

| | |
|:---|:---|
|  | <br> */s/ Rita I. Jain, M.D.* |
| Name: | Rita I. Jain, M.D. |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Jain Rita<br><sub>(Last) (First) (Middle)</sub><br>C/O CELLDEX THERAPEUTICS, INC.<br>53 FRONTAGE ROAD, SUITE 220<br><sub>(Street)</sub><br>HAMPTON, NJ 08827<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Celldex Therapeutics, Inc. [ CLDX ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2023-02-16 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director   [ ] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |

---

**Remarks:**
Exhibit 24 - Power of Attorney

**Signature:** /s/ Sam Martin, attorney-in-fact for Rita Jain  
**Date:** 2023-02-21

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**